Month: April 2025

Reference is made to IDEX Biometrics ASA’s announcement on 14 April 2025 regarding a notice of large shareholding. By inadvertence, the announcement contained some minor errors in the shareholders name and new number of shares. Please see correct notification below: IDEX Biometrics ASA discloses the following on behalf of a shareholder. Reference is made to the notice by IDEX Biometrics on 11 April 2025 that the Extraordinary General Meeting of the company had, subject to the registration of a share capital reduction, resolved to issue 3,000,000,000 shares in a debt conversion, thereby increasing the number of shares in the company to 3,831,594,232. A close associate of Robert Keith, Charles Street International Ltd., will, subject to the registration of the capital reduction, be allocated 1,000,000,000 shares in the debt conversion and...

SINGAPORE, April 15, 2025 (GLOBE NEWSWIRE) — EngageLab, a world-leading provider of AI-powered omnichannel customer engagement solutions, is proud to support the remarkable growth of a prominent Chinese cross-border B2B e-commerce platform, which recently surged to the #2 spot on the U.S. free iPhone app rankings, second only to ChatGPT. This unprecedented rise highlights the platform’s growing influence in the U.S. market and underscores the importance of cutting-edge email solutions in driving its success. The platform’s rapid ascent comes amidst heightened interest in Chinese cross-border e-commerce, fueled by viral TikTok videos showcasing Chinese factories and their role in global manufacturing. This surge in visibility has led to a dramatic increase in app downloads, with U.S. downloads growing by 940% in just a few days....

MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) — Pierluigi Paracchi, CEO Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at “Montalcini Global Biotech Tour” in Doha, Qatar on April 17th, 2025 at the Sheikh Fahad bin Jassim Al Thani theatre, Ministry of Commerce and Industry (MOCI) Building. Following the announcement of a €20 million ($22.7 million) strategic financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) — aimed at expanding Genenta’s pipeline with the advancement of Temferon™ in metastatic Renal Cell Cancer (mRCC) — and the addition of approximately €3.0 million ($3.2 million) raised via at-the-market (ATM) facility, Genenta CEO Pierluigi Paracchi will present at the event, which will be hosted by H.E....

SHENZHEN, China, April 15, 2025 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that its subsidiary EngageLab, a world-leading provider of AI-powered omnichannel customer engagement solutions, is honored to support the remarkable growth of a prominent Chinese cross-border B2B e-commerce platform, which recently surged to the #2 spot on the U.S. free iPhone app rankings, second only to ChatGPT. This unprecedented rise highlights the platform’s growing influence in the U.S. market and underscores the importance of cutting-edge email solutions in driving its success. The platform’s rapid ascent comes amidst heightened interest in Chinese cross-border e-commerce, fueled...

Q1 2025 Results Release and Conference Call Thursday, May 15th, 2025 Vallourec will publish First Quarter 2025 Results on May 15th, 2025 at 07:30 AM CET. Philippe Guillemot, Chairman of the Board and Chief Executive Officer, and Sascha Bibert, Chief Financial Officer are pleased to invite you to a presentation of the results via conference call and audiocast at 09:30 AM CET. To connect to the audiocast (live and replay), please visit: https://channel.royalcast.com/landingpage/vallourec-en/20250515_1/ To participate in the call, please dial:UK (Standard International Access): +44 (0) 33 0551 0200 US: +1 786 697 3501 FR: +33 (0) 1 70 37 71 66Password: Vallourec The presentation will be available from 09:00 AM CET on Vallourec’s website: https://www.vallourec.com/en/investors About Vallourec Vallourec is a world leader in premium...

Ageas successfully raised EUR 550 million through an accelerated bookbuild offering Ageas SA/NV (“Ageas” or the “Company”) announces that it has successfully raised EUR 550 million by way of an accelerated bookbuild offering of 10,967,099 new ordinary shares in the Company (the “New Shares”), which was announced on 14 April 2025 (the “Share Placement”). The New Shares have been placed at a price of EUR 50.15 per New Share (the “Issue Price”). The Share Placement is intended to partly finance the acquisition of esure1 to establish a top-3 UK personal lines platform, as announced yesterday (the “Transaction”). The Transaction is expected to generate an unlevered return on investment of over 12% for Ageas, translating in a levered return on invested capital (ROIC) in excess of 20%. For more details, please visit the following link: https://ageas.com/en/esure-2025.1...

April 15, 2025Announcement no. 11                                                                          Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S Copenhagen, Denmark, April 15, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announces that the private placement of 25,000,000 new shares has been completed. The initiation of the private placement was announced yesterday in company announcement 10. Peter Mørch Eriksen, CEO of BioPorto, says: “I am delighted by the strong commitments from both our largest existing shareholders and new investors drawn to our company and the investment case. The continuous support of our owners and...

April 15, 2025Announcement no. 11                                                                          Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S Copenhagen, Denmark, April 15, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announces that the private placement of 25,000,000 new shares has been completed. The initiation of the private placement was announced earlier today in company announcement 10. Peter Mørch Eriksen, CEO of BioPorto, says: “I am delighted by the strong commitments from both our largest existing shareholders and new investors drawn to our company and the investment case. The continuous support of our owners...